Italia markets close in 3 hours 30 minutes

CNTB May 2024 2.500 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,05000,0000 (0,00%)
In data: 01:50PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,0500
Aperto0,0500
Denaro0,0000
Lettera0,0500
Prezzo d'esercizio2,50
Scadenza2024-05-17
Min-Max giorno0,0500 - 0,0500
Contratto - Min-MaxN/D
Volume20
Open Interest22
  • GlobeNewswire

    Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

    Key data readouts with Company’s lead drug candidate rademikibart expected in the fourth quarter of 2023 Topline results from Stage 2 of the China pivotal trial in atopic dermatitisTopline results from Global Phase 2 trial in asthma Cash balance of $131.6 million expected to support planned operations into at least 2026 SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage

  • GlobeNewswire

    Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

    SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that on September 11, 2023, it received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC (

  • GlobeNewswire

    Connect Biopharma to Participate in Upcoming September Investor Conferences

    SAN DIEGO and TAICANG, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Connect Biopharma’s management team will participate at the following upcoming investor conferences: H.C. Wainwright 25th